Tamoxifen treatment failures in hormonally responsive breast cancers correlation with steroid receptors

Norman D. Bloom, Jerry H. Fishman

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Clinical correlation of treatment response with estrogen (ERP) and progesterone (PgRP) receptors in 81 patients revealed a remission rate of 76% if both receptors were present in the tumor. The response rate was 89% in those patients with positive receptors in whom an endocrine ablative procedure was performed and was 63% in those patients treated with tamoxifen, suggesting that the latter modality may not be effective in the treatment of some hormonally responsive tumors. An assay to determine receptor sensitivity to tamoxifen was developed and correlated with clinical response to tamoxifen treatment. Of the 56 human breast tumors analyzed, 29 tumors were ERP‐ and PgRP‐positive and ten of these were tamoxifen‐insensitive. Sixteen tumors were ERP‐ and PgRP‐negative and tamoxifen‐insensitive. Of the remaining 11 tumors, four were tamoxifen‐sensitive. Nineteen of the 56 patients whose tumors were analyzed were treated for advance breast cancers with tamoxifen. Twelve patients who were ERP‐ and PgRP‐positive and tamoxifen‐sensitive responded to this modality of treatment. Seven treatment failures were noted in this group all of whom were ERP‐positive and tamoxifen‐insensitive. Endocrine ablation failed either prior or subsequently in three of these patients all of whom were PgRP‐negative. Two patients who were ERP‐ and PgRP‐positive and tamoxifen‐insensitive sub‐sequently responded to an alternative antihormonal treatment.

Original languageEnglish
Pages (from-to)1190-1194
Number of pages5
JournalCancer
Volume51
Issue number7
DOIs
StatePublished - 1 Apr 1983
Externally publishedYes

Fingerprint

Dive into the research topics of 'Tamoxifen treatment failures in hormonally responsive breast cancers correlation with steroid receptors'. Together they form a unique fingerprint.

Cite this